Wednesday 20 May 2026

One To Watch

Braeburn Pharmaceuticals


Want to Update your Company's Profile?


Latest Braeburn Pharmaceuticals News

Braeburn's Brixadi becomes new option for opioid use disorder
24 May 2023
FDA ordered to reconsider Braeburn's application for final approval of Brixadi
24 July 2019
Braeburn gains tentative FDA approval of Brixadi
24 December 2018
Extended-release opioid use disorder drugs 'priced beyond benefits'
4 December 2018
More Braeburn Pharmaceuticals news >


Today's issue

AMR Bio launches with Phase III-ready antimicrobial
Biotechnology
AMR Bio launches with Phase III-ready antimicrobial
20 May 2026
Pharmaceutical
Supreme Court rejects bid to halt IRA price negotiations
20 May 2026
Pharmaceutical
Dysport edges Botox on durability in spasticity head-to-head
20 May 2026
Pharmaceutical
WHO declares Ebola outbreak global emergency
20 May 2026
Biotechnology
Mentari lists via InMed merger, takes $290m for migraine pipeline
20 May 2026
Pharmaceutical
Negative US court decision for Takeda
20 May 2026
Biotechnology
Amgen announces CFO Peter Griffith retiring
20 May 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze